Precision BioSciences prices $125M stock offering at $7.75
Precision BioSciences (DTIL) priced a $125M stock offering at $7.75 per share, including 10.2M shares and warrants. Proceeds will fund R&D for PBGENE-HBV and PBGENE-DMD, plus working capital. The offering is expected to close Friday, with TD Cowen and Guggenheim Securities as joint book-runners.
How this was made
The 30-second read
Why it matters
The offering increases cash but dilutes equity, likely pressuring the share price in the near term.
Market read
Primary disclosure of a sizable capital raise for a biotech firm; traders may adjust positions today.
What to watch
Potential strategic investors in the offering may bring partnerships or validation.
Background
Precision BioSciences announced the pricing of a $125M equity offering to fund R&D and working capital.
Ticker impact
Precision BioSciences priced a $125M underwritten public offering at $7.75 per share.
likely downward pressure as the market prices in dilution
Primary disclosure of a sizable capital raise; dilution is a well‑known catalyst for price decline.
Market effects
Adds capital to the gene‑editing biotech sector, may spur competitor financing activity.
U.S. biotech financing environment sees additional supply.
Limited to biotech investors; no broad market effect.
Counterpoint
If the raised capital funds promising pipelines, the long‑term upside could outweigh short‑term dilution.
Key entities
- companyPrecision BioSciences Inc.
Clinical‑stage gene editing firm issuing new shares.
- financial_institutionTD Cowen
Joint book‑running manager for the offering.
